StockData
Sanofi logo

Sanofi (SNY) stock

SNYNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as SNYNF
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Feb 17, 2026Score 6/30
$44.34+1.21 (+2.81%)

Close on Oct 30, 2026Market cap $108.14BP/E 12.4Yield –

Earnings

Sanofi's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue, Q2 FY2023
€11.96B
Business EPS, Q2 FY2023
2.55 EUR
Latest guidance
Issued
Oct 27, 2023 · 3 items

Quarterly results

Revenue and earnings per share from each of Sanofi's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q2 FY2025ended Jun 30, 2025Oct 27, 2025before the open––––Release
Q2 FY2023ended Jun 30, 2023Oct 27, 2023during market hours€11.96B–2.01 EUR2.55 EURRelease

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Sanofi's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
expected one-off COVID vaccine revenuesQ4 FY2023400–NewOct 27, 2023
currency impact on 2023 business EPSnon-GAAPFY2023-7% – -6%–NewOct 27, 2023
effective tax ratenon-GAAPFY202319%–NewOct 27, 2023

Guidance history

Every forecast Sanofi put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Oct 27, 2023currency impact on 2023 business EPSFY2023-7% – -6%New
Oct 27, 2023effective tax rateFY202319%New
Oct 27, 2023expected one-off COVID vaccine revenuesQ4 FY2023400New

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Sanofi filed with the SEC as exhibits to Form 8-K or 6-K

  1. Sanofi breaks ground on new state-of-the-art insulin manufacturing facility in Germany
    6-K
  2. Sanofi and Regeneron expand global Alliance with multiple
    6-K
  3. Sanofi and Cheplapharm to create new strategic partnership in mature medicines
    6-K
  4. Sanofi’s MenQuadfi approved in the EU for use in infants from age six weeks
    6-K
  5. 1. Condensed half-year consolidated financial statements
    6-K
  6. A/ Significant events of the first half of 2026
    6-K
  7. Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded
    6-K
  8. Sanofi evolves its Executive Committee to support its next strategic chapter
    6-K
  9. Sanofi announces decision not to submit amlitelimab in atopic dermatitis for global
    6-K
  10. Sanofi’s subcutaneous Sarclisa Escena approved in the US as first anticancer treatment
    6-K
  11. Sanofi’s Nexviazyme met all primary and secondary endpoints in infantile-onset Pompe disease phase 3 study
    6-K
  12. Sanofi’s Sarclisa subcutaneous formulation approved in Japan for patients with multiple myeloma
    6-K
  13. Sanofi appoints Paulo Fontoura as Global Head of R&D
    6-K
  14. Sanofi’s Cenrifki (tolebrutinib) approved in the EU as the first disability-targeting medicine for
    6-K
  15. Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients
    6-K